• Latest
    • Big pharma
    • Biotechnology
    • CRISPR
    • Generics
    • Unified Patent Court
  • Regions
    • Americas
    • Europe
    • Asia
    • Asia-Pacific
  • Careers
  • Events
    • Conferences
    • Conference Videos
    • Webinars
  • Directory
  • Magazines
  • About
  • Contact
  • Newsletter
  • Login
  • Subscribe
  • Home
  • About
  • Contact
  • Newsletter
  • Login


Subscribe
  • Home
  • Trends at the Patent Trial and Appeal Board of the US Patent and Trademark Office: Is the Pendulum Beginning to Swing for Owners of Life Sciences Pate
18 March 2021

Trends at the Patent Trial and Appeal Board of the US Patent and Trademark Office: Is the Pendulum Beginning to Swing for Owners of Life Sciences Pate

The Patent Trial and Appeal Board is an important forum for determining a US patent’s validity. Since 2012, when inter partes review of US patents began, the PTAB’s cancellation rate for challenged patents has varied dramatically.

Already registered?

Login to your account


If you don't have a login or your access has expired, you will need to purchase a subscription to gain access to this article, including all our online content.

For more information on individual annual subscriptions for full paid access and corporate subscription options please contact us.

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk




Editor's picks

US govt backs Hikma over ‘skinny label’ rules
Americas
US govt backs Hikma over ‘skinny label’ rules
9 December 2025

Editor's picks

Americas
US govt backs Hikma over ‘skinny label’ rules
9 December 2025
Europe
Biotech cleared to make biosimilar of $6bn treatment after landmark ruling
25 November 2025
Americas
INTA votes in new 2026 president at Florida leadership meeting
20 November 2025
Asia
WIPR Rankings reveals the go-to firms and attorneys for China patent work
7 November 2025
Americas
New AIPLA president calls for greater certainty in US patent law
6 November 2025
Unified Patent Court
Regeneron and CureVac: UPC ‘cannot be ignored’
4 November 2025

More features

Novo Nordisk ramps up semaglutide defence as generics lurk
Cooley drafts in 30-strong life sciences team from rival
US govt backs Hikma over ‘skinny label’ rules
Marks & Clerk adds multi-jurisdictional disputes expert
USPTO issues guidance to support patent eligibility declarations
Chest-worn heart monitor tech flatlines in US patent appeal
Novo Nordisk India strategy suffers semaglutide patent setback
FedCirc voids Seagen patent in $41m cancer treatment dispute

  • Home
  • News
  • About us
  • Contact
  • Terms of Use
  • Privacy Policy
  • Terms of Subscription

LSIPR
Newton Media Ltd
Kingfisher House
21-23 Elmfield Road
BR1 1LT
United Kingdom

  • Twitter
  • Linkedin